Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Franck Carbonnel; Emilie Soularue; Clélia Coutzac; Nathalie Chaput; Christine Mateus; Patricia Lepage; Caroline Robert

doi:10.1007/s00281-016-0613-x

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Franck Carbonnel, Emilie Soularue, Clélia Coutzac, Nathalie Chaput, Christine Mateus, Patricia Lepage, Caroline Robert

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

20 Citations (Scopus)

Résumé

Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident T_reg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.

langue originale	Anglais
Pages (de - à)	327-331
Nombre de pages	5
journal	Seminars in Immunopathology
Volume	39
Numéro de publication	3
Les DOIs	https://doi.org/10.1007/s00281-016-0613-x
état	Publié - 1 avr. 2017

Accès au document

10.1007/s00281-016-0613-x

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{8c8fbda8070e45238da737cb0da07ee5,

title = "Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?",

abstract = "Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident Treg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.",

author = "Franck Carbonnel and Emilie Soularue and Cl{\'e}lia Coutzac and Nathalie Chaput and Christine Mateus and Patricia Lepage and Caroline Robert",

note = "Publisher Copyright: {\textcopyright} 2017, Springer-Verlag Berlin Heidelberg.",

year = "2017",

month = apr,

day = "1",

doi = "10.1007/s00281-016-0613-x",

language = "English",

volume = "39",

pages = "327--331",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

number = "3",

}

TY - JOUR

T1 - Inflammatory bowel disease and cancer response due to anti-CTLA-4

T2 - is it in the flora?

AU - Carbonnel, Franck

AU - Soularue, Emilie

AU - Coutzac, Clélia

AU - Chaput, Nathalie

AU - Mateus, Christine

AU - Lepage, Patricia

AU - Robert, Caroline

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident Treg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.

AB - Checkpoint inhibitors blocking CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) have transfigured our cancer treatment paradigm. However, these drugs can induce immune-related adverse events that share clinical and pathological characteristics with immune-mediated diseases. One of the most severe immune-related adverse event observed with anti-CTLA-4 is an enterocolitis that mirrors naturally occurring inflammatory bowel disease. This paper reviews the clinical, immunological, and microbiota data associated with the immune-related enterocolitis induced by the cancer immunotherapy blocking CTLA-4, ipilimumab. A parallel analysis of the mechanisms underlying inflammatory bowel diseases on the one hand, and anti-CTLA-4-induced colitis on the other hand, stresses the crucial role of the gut microbiota and of resident Treg in the genesis of both iatrogenic and spontaneous inflammatory bowel diseases.

UR - http://www.scopus.com/inward/record.url?scp=85009461435&partnerID=8YFLogxK

U2 - 10.1007/s00281-016-0613-x

DO - 10.1007/s00281-016-0613-x

M3 - Review article

C2 - 28093620

AN - SCOPUS:85009461435

SN - 1863-2297

VL - 39

SP - 327

EP - 331

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

IS - 3

ER -